Chabon, Jacob J.
Hamilton, Emily G. http://orcid.org/0000-0001-7955-6244
Kurtz, David M. http://orcid.org/0000-0002-6382-4651
Esfahani, Mohammad S.
Moding, Everett J.
Stehr, Henning
Schroers-Martin, Joseph
Nabet, Barzin Y. http://orcid.org/0000-0002-4824-3533
Chen, Binbin http://orcid.org/0000-0003-2973-2718
Chaudhuri, Aadel A. http://orcid.org/0000-0003-3115-3061
Liu, Chih Long
Hui, Angela B.
Jin, Michael C.
Azad, Tej D.
Almanza, Diego
Jeon, Young-Jun
Nesselbush, Monica C.
Co Ting Keh, Lyron
Bonilla, Rene F.
Yoo, Christopher H. http://orcid.org/0000-0003-2132-8956
Ko, Ryan B. http://orcid.org/0000-0002-2123-9702
Chen, Emily L.
Merriott, David J.
Massion, Pierre P.
Mansfield, Aaron S. http://orcid.org/0000-0002-9483-6903
Jen, Jin
Ren, Hong Z.
Lin, Steven H.
Costantino, Christina L. http://orcid.org/0000-0002-4525-3533
Burr, Risa
Tibshirani, Robert
Gambhir, Sanjiv S. http://orcid.org/0000-0002-2711-7554
Berry, Gerald J.
Jensen, Kristin C.
West, Robert B.
Neal, Joel W.
Wakelee, Heather A.
Loo, Billy W. Jr http://orcid.org/0000-0002-2521-0544
Kunder, Christian A.
Leung, Ann N.
Lui, Natalie S.
Berry, Mark F.
Shrager, Joseph B.
Nair, Viswam S. http://orcid.org/0000-0001-6376-8154
Haber, Daniel A.
Sequist, Lecia V. http://orcid.org/0000-0002-8965-6991
Alizadeh, Ash A. http://orcid.org/0000-0002-5153-5625
Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Article History
Received: 30 July 2019
Accepted: 13 February 2020
First Online: 25 March 2020
Competing interests
: D.M.K. reports paid consultancy from Roche Molecular Diagnostics. A.A.C. reports speaker honoraria and travel support from Roche Sequencing Solutions, Varian Medical Systems, and Foundation Medicine, a research grant from Roche Sequencing Solutions, and has served as a paid consultant for Fenix Group International. A.S.M. reports advisory for AbbVie, Genentech, and Bristol-Myers Squibb (honoraria paid to institution) and research funding from Novartis and Verily. J.J. is now employed by Celgene. S.H.L. reports paid advisory from AstraZeneca, speaker honoraria from Varian Medical Systems and research funding from BeyondSpring Pharmaceuticals Inc., Hitachi Chemical Diagnostics, Genentech, and New River Labs. S.S.G. reports paid consultancy from AbbVie, Ceremark, CytomX Therapeutics Inc., GPV, Life Molecular Imaging, Nusano, Spectrum Dynamics, and TPG, and ownership interest in Akrotome Imaging Inc., Cellsight Technologies, CytomX Therapeutics Inc., Earli Inc., Endra Inc., MagArray Inc., Nines, Nodus Therapeutics, Nusano, RefleXion Medical Inc., SiteOne Therapeutics Inc., Spectrum Dynamics, Vave Health, and Vor Biopharma. J.W.N. reports paid consultancy from AstraZeneca, Genentech, Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, and Calithera Biosciences, and research funding from Genentech, Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune and GSK. H.A.W. reports paid advisory from AstraZeneca, Xcovery, Janssen, and Mirati, unpaid advisory from Merck, Takeda, Genentech, Roche, and Cellworks, and research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery. A.A.A. reports ownership interest in CiberMed and FortySeven Inc., patent filings related to cancer biomarkers, and paid consultancy from Genentech, Roche, Chugai, Gilead, and Celgene. M.D. reports research funding from Varian Medical Systems and Illumina, ownership interest in CiberMed, patent filings related to cancer biomarkers, and paid consultancy from Roche, AstraZeneca, RefleXion and BioNTech. The remaining authors declare no potential conflicts of interest.